Qualigen is a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics. The FastPack® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics since 2002. Our therapeutics pipeline includes cancer drug compounds such as QN-302, RAS, QN-247, as well as STARS, a DNA/RNA-based treatment device. By combining our demonstrated ability to develop and commercialize innovative medical products with the advanced capabilities of leading cancer research centers, such as the University of Louisville, we are committed to providing exciting new therapeutic technologies to physicians and patients.